Cargando…
Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy
We investigated the relationship between self-reported adherence to pancreatic enzyme replacement therapy (PERT), nutritional status, and all-cause hospitalization in cystic fibrosis (CF) patients with a record of PERT use. Association of self-reported annual PERT use rate (adherence) with annual ho...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985972/ https://www.ncbi.nlm.nih.gov/pubmed/31984768 http://dx.doi.org/10.1177/1479973119900612 |
_version_ | 1783491885816348672 |
---|---|
author | Trapnell, Bruce C. Chen, Su Khurmi, Rupal Bodhani, Amit Kapoor, Mudra Haupt, Mark |
author_facet | Trapnell, Bruce C. Chen, Su Khurmi, Rupal Bodhani, Amit Kapoor, Mudra Haupt, Mark |
author_sort | Trapnell, Bruce C. |
collection | PubMed |
description | We investigated the relationship between self-reported adherence to pancreatic enzyme replacement therapy (PERT), nutritional status, and all-cause hospitalization in cystic fibrosis (CF) patients with a record of PERT use. Association of self-reported annual PERT use rate (adherence) with annual hospital admission rate (HAR) and annual total hospital nights (THNs) were analyzed for 5301 children (2000–2012) and 13,989 adults (2000–2013) from the CF Foundation Patient Registry. Multivariate linear regression was used to determine the association of HAR and THN with mean annual PERT use rate, cumulative PERT use rate, mean body mass index (BMI) (adult) or BMI percentile (pediatric), age, and sex. The median annual PERT use rate was 87% in children and 80% in adults. Statistically, higher annual PERT use, longer cumulative PERT, and higher BMI percentile (children) or BMI (adults) were significantly (p < 0.0001) associated with lower annual HAR and fewer annual THN in children and adults. Female sex was associated with higher annual HAR and more annual THN in children and adults (p < 0.05). Results indicate self-reported adherence to PERT, increased BMI, and male sex were associated with fewer hospital admissions and annual hospital nights in CF patients. |
format | Online Article Text |
id | pubmed-6985972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-69859722020-02-11 Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy Trapnell, Bruce C. Chen, Su Khurmi, Rupal Bodhani, Amit Kapoor, Mudra Haupt, Mark Chron Respir Dis Original Paper We investigated the relationship between self-reported adherence to pancreatic enzyme replacement therapy (PERT), nutritional status, and all-cause hospitalization in cystic fibrosis (CF) patients with a record of PERT use. Association of self-reported annual PERT use rate (adherence) with annual hospital admission rate (HAR) and annual total hospital nights (THNs) were analyzed for 5301 children (2000–2012) and 13,989 adults (2000–2013) from the CF Foundation Patient Registry. Multivariate linear regression was used to determine the association of HAR and THN with mean annual PERT use rate, cumulative PERT use rate, mean body mass index (BMI) (adult) or BMI percentile (pediatric), age, and sex. The median annual PERT use rate was 87% in children and 80% in adults. Statistically, higher annual PERT use, longer cumulative PERT, and higher BMI percentile (children) or BMI (adults) were significantly (p < 0.0001) associated with lower annual HAR and fewer annual THN in children and adults. Female sex was associated with higher annual HAR and more annual THN in children and adults (p < 0.05). Results indicate self-reported adherence to PERT, increased BMI, and male sex were associated with fewer hospital admissions and annual hospital nights in CF patients. SAGE Publications 2020-01-26 /pmc/articles/PMC6985972/ /pubmed/31984768 http://dx.doi.org/10.1177/1479973119900612 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Paper Trapnell, Bruce C. Chen, Su Khurmi, Rupal Bodhani, Amit Kapoor, Mudra Haupt, Mark Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy |
title | Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy |
title_full | Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy |
title_fullStr | Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy |
title_full_unstemmed | Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy |
title_short | Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy |
title_sort | hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985972/ https://www.ncbi.nlm.nih.gov/pubmed/31984768 http://dx.doi.org/10.1177/1479973119900612 |
work_keys_str_mv | AT trapnellbrucec hospitalizationratesamongpatientswithcysticfibrosisusingpancreaticenzymereplacementtherapy AT chensu hospitalizationratesamongpatientswithcysticfibrosisusingpancreaticenzymereplacementtherapy AT khurmirupal hospitalizationratesamongpatientswithcysticfibrosisusingpancreaticenzymereplacementtherapy AT bodhaniamit hospitalizationratesamongpatientswithcysticfibrosisusingpancreaticenzymereplacementtherapy AT kapoormudra hospitalizationratesamongpatientswithcysticfibrosisusingpancreaticenzymereplacementtherapy AT hauptmark hospitalizationratesamongpatientswithcysticfibrosisusingpancreaticenzymereplacementtherapy |